Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05154994
Title Tremelimumab, Durvalumab, and Belinostat for the Treatment of ARID1A Mutated Metastatic or Unresectable, Locally Advanced Urothelial Carcinoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Utah
Indications

transitional cell carcinoma

Therapies

Belinostat + Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST